CRA experts advised counsel and presented before the FTC on transactions involving Novartis’ acquisition of cancer drugs from GlaxoSmithKline, GSK’s joint venture with Novartis on consumer health, and Novartis’s sale of Novartis Animal Health to Eli Lilly & Co. The deals ultimately went forward with certain divestitures.
Josh Sherman rejoins CRA's Antitrust & Competition Practice
“We are thrilled to welcome Josh back to our team,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “Josh’s deep expertise...